Checkpoint-inhibitors like nivolomab and pembrolizumab, targeting programmed cell death-1 (PD-1), or ipilimumab, blocking CTLA-4, can induce adverse autoimmune reactions like hepatitis, colitis, rash, endocrinopathies and pneumonitis [131]. This evidence concerns the gene PDCD1 and hepatitis A virus infection.